Mike Wells Fargo has initiated coverage of Arcus Biosciences ( NYSE: RCUS ) with an outperform rating saying that the company's renal cell carcinoma candidate, casdatifan, has best-in-class potential. The firm has a price target of $29 (~66% upside based on Oct. 8 close).
Analyst.
